We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Safety monitoring and information (121)
- Compliance and enforcement (32)
- Import and export (28)
- Shortages and supply disruptions (17)
- Sunscreens (7)
- Advertising (6)
- COVID-19 (5)
- Labelling and packaging (4)
- Weight loss products (4)
- Breast implant hub (3)
- Manufacturing (3)
- Legislation (2)
- Metal-on-metal hip replacement implants hub (1)
Type of content
Search
1030 result(s) found, displaying 976 to 1000
-
Safety alertsWeight loss drug Sibutramine (Reductil) under safety review for cardiovascular risks.
-
Safety alertsWe are advising that there are supply issues with Physeptone (methadone) tablets due to quality control problems.
-
Safety alertsApproval has been granted for the Panvax H1N1 vaccine in children starting at 6 months, with Panvax H1N1 Junior for ages 6 months to 3 years.
-
Safety alertsIn October 2009 an anaphylactic reaction to the Panvax H1N1 pandemic influenza vaccine was reported in Western Australia in a person known to have a pre-existing latex allergy.
-
Safety alerts
-
-
Safety alertsGinkgo biloba products with high quercetin and rutin levels have been identified. Quality standards are being reviewed.
-
Safety alertsPanvax H1N1 influenza vaccine has been approved for use in adults and children over 10 years old, with additional data needed for younger children.
-
Safety alertsAdvise to exercise caution when using Australian Hydroxycut products
-
Market actionsChuan Xiong Cha Tiao Wan pills have been recalled due to the presence of aristolochic acids, which can cause severe kidney damage and urinary tract cancer. Stop using them immediately and consult your doctor for advice.
-
Market actions
-
Market actions
-
-
-
-
-
Market actionsA number of brands of hot/cold gel packs are being recalled following testing by the Therapeutic Goods Administration (TGA) of contents for ethylene glycol, a toxic substance.
-
Market actionsA number of brands of hot/cold gel packs are being recalled following testing by the Therapeutic Goods Administration (TGA) of contents for ethylene glycol, a toxic substance. Testing was undertaken following the previous recall of Thermoskin® hot/cold gel packs to determine if the problem was more widespread.
-
Market actionsThe Therapeutic Goods Administration (TGA) advised on 2 September 2008 that the Thermoskin® brand of hot/cold gel packs was being recalled after testing revealed that they contained the toxic substance ethylene glycol, rather than the non-toxic ingredient propylene glycol.
-
Safety alerts
-
Safety alerts
-
Market actionsClexane (enoxaparin) is being recalled due to contamination concerns, and patients should check with their doctor or pharmacist to see if their supply is affected.
-
Market actionsConsumers should stop using Clexane (enoxaparin) from the newly recalled batch due to impurity concerns. Check with your doctor or pharmacist to see if your supply is affected and return any contaminated product. If you have any concerns, consult your doctor.
-
-
Market actionsCertain batches of Clexane (enoxaparin) have been recalled because of an impurity. Stop using it, check with your healthcare provider, and return any affected product. If you have concerns, consult your doctor.